13d • General discussion
🧬 KPV Peptide: Shutting Down NF-κB – A Quick Research Breakdown
What Is KPV?
A tripeptide (Lysine-Proline-Valine) derived from α-MSH. Retains potent anti-inflammatory properties without pigmentation effects.
How KPV Inhibits NF-κB:
1. Blocks p65 Nuclear Import
- Inhibits nuclear translocation of p65RelA subunit
- Competes with Imp-α3 binding site
- Prevents transcription of inflammatory genes
2. Suppresses MAPK/NF-κB Axis
- Reduces ROS production
- Inhibits ERK & p38 MAPK pathways
- Blocks downstream NF-κB activation
- Reduces IL-1β & apoptosis-related proteins (Bax, Bcl-2)
3. IL-1β Inhibition
- Antimigratory effect not blocked by MC3/4-R antagonists
- Does not elevate cAMP (distinct from MSH peptides)
- Active in IL-1β-induced peritonitis models
4. PepT1-Mediated Uptake
- Transported by di/tripeptide transporter PepT1
- Relevant for intestinal inflammation research
- Oral KPV reduces colitis incidence in models
Research Applications:
- Dermatology (pollution-induced skin inflammation)
- Pulmonary (asthma, IL-8/eotaxin suppression)
- Gastroenterology (IBD, intestinal inflammation)
Purity Standards:
- Research-grade >98% purity
- Lyophilized powder for research use
Takeaway:
KPV offers a unique mechanism for NF-κB inhibition, distinct from classical melanocortin receptor pathways.
⚠️ Research only. Not for human consumption.
0
0 comments
🧬 KPV Peptide: Shutting Down NF-κB – A Quick Research Breakdown
powered by
skool.com/biohacking-and-longevity-group-3757
All-in-one peptide education community. 🧪
Dosing guides, storage protocols, stacking frameworks, vendor intel, GLP-1 research, and expert support.🧬
Suggested communities
Powered by